Regulatory Travere claims first FDA OK in rare kidney disease FSGS PharmaphorumShrugging off an earlier phase 3 disappointment, Travere's Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.RegulatoryRare DiseaseRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS. RegulatoryRare DiseaseRead full story Post navigation Previous: Novo Nordisk and OpenAI forge alliance to drive speedy drug developmentNext: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026